[(3aR,5S,6R,6aR)-6-(azidomethyl)-2,2-dimethyl-3a,5,6,6a-tetrahydrofuro[2,3-d][1,3]dioxol-5-yl]methoxy-tert-butyl-dimethylsilane | 146035-68-9

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: [(3aR,5S,6R,6aR)-6-(azidomethyl)-2,2-dimethyl-3a,5,6,6a-tetrahydrofuro[2,3-d][1,3]dioxol-5-yl]methoxy-tert-butyl-dimethylsilane
• 英文别名: 3-(azidomethyl)-3-deoxy-5-O-<(tert-butyldimethyl)silyl>-1,2-O-isopropylidene-α-D-ribofuranose；3-(azidomethyl)-3-deoxy-5-O-[(tert-butyldimethyl)silyl]-1,2-O-isopropylidene-α-D-ribofuranose
• CAS: 146035-68-9
• 化学式: C₁₅H₂₉N₃O₄Si
• 分子量: 343.498
• InChiKey: JWONEYKQPWYSJG-FDYHWXHSSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.81
• 重原子数：
  23
• 可旋转键数：
  6
• 环数：
  2.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  51.3
• 氢给体数：
  0
• 氢受体数：
  6

反应信息

• 作为反应物：
  描述：

  [(3aR,5S,6R,6aR)-6-(azidomethyl)-2,2-dimethyl-3a,5,6,6a-tetrahydrofuro[2,3-d][1,3]dioxol-5-yl]methoxy-tert-butyl-dimethylsilane 在 4-二甲氨基吡啶 、 ruthenium trichloride 、 sodium periodate 、 四丁基氟化铵 、 盐酸-N-乙基-Nˊ-(3-二甲氨基丙基)碳二亚胺 作用下， 以 四氢呋喃 、 氯仿 、 水 、 乙腈 为溶剂， 反应 55.5h， 生成 methyl 3-azidomethyl-3-deoxy-1,2-isopropylidene-α-D-ribofuronamide
  参考文献：
  名称：

  Exploring human adenosine A3 receptor complementarity and activity for adenosine analogues modified in the ribose and purine moiety

  摘要：

  In this paper we investigated the influence on affinity, selectivity and intrinsic activity upon modification of the adenosine agonist scaffold at the 3- and 5'-positions of the ribofuranosyl moiety and the 2- and N-6-positions of the purine base. This resulted in the synthesis of various analogues, that is, 3-12 and 24-33, with good hA(3)AR selectivity and moderate-to-high affinities (as in 32, K-i = 27 nM). Interesting was the ability to tune the intrinsic activity depending on the substituent introduced at the 3'-position. (C) 2004 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2004.11.044
• 作为产物：
  描述：

  1,2-O-isopropylidene-5-O-(tert-butyl)dimethylsilyl-α-D-xylofuranoside 在 四氢呋喃 、 吡啶 、 chromium(VI) oxide 、 sodium hydroxide 、 叠氮化锂 、 硼烷 、 双氧水 、 乙酸酐 、 sodium hydride 作用下， 以 二氯甲烷 、 N,N-二甲基甲酰胺 为溶剂， 反应 34.5h， 生成 [(3aR,5S,6R,6aR)-6-(azidomethyl)-2,2-dimethyl-3a,5,6,6a-tetrahydrofuro[2,3-d][1,3]dioxol-5-yl]methoxy-tert-butyl-dimethylsilane
  参考文献：
  名称：

  Syntheses and biological evaluations of 3'-deoxy-3'-C-branched-chain-substituted nucleosides

  摘要：

  Various 3'-deoxy-3'-C-(hydroxymethyl)-, 3'-deoxy-3'-C-(fluoromethyl)-, 3'-deoxy-3'-C-(azidomethyl)-, and 3'-deoxy-3'-C-(aminomethyl)-substituted nucleosides (total 12 compounds) have been synthesized and evaluated against L1210, P388, S-180, and CCRF-CEM cells and HSV-1, HSV-2, and HIV-1 in culture. Only 3'-deoxy-3'-C-(hydroxymethyl)thymidine (36) was found to show significant anticancer activity against L1210, P388, S-180, and CCRF-CEM cells with ED50 values of 50, 5, 10, and 1 muM, respectively. None of these compounds demonstrated significant antiviral activity against HSV-1, HSV-2, or HIV-1. These compounds were also evaluated against thymidine kinases derived from HSV-1 (strain KOS), HSV-2 (strain 333), and mammalian (K562) cells. The thymidine kinase (HSV-1 strain KOS) was inhibited significantly by both 3'-deoxy-3'-C-(hydroxymethyl)- and 3'-deoxy-3'-C-(fluoromethyl)thymidine.

  DOI：

  10.1021/jm00055a006

文献信息

• Synthesis of an aza analogue of 2-deoxy-d-ribofuranose and its homologues
  作者：Vyacheslav V Filichev、Malene Brandt、Erik B Pedersen

  DOI：10.1016/s0008-6215(01)00132-x

  日期：2001.7

  Azasugars were obtained in one-pot reactions by catalytic reduction reactions of amino group precursors in aldosugars followed by intramolecular reductive amino alkylation reactions. (3R,4S)-4-[(1S)-1,2-Dihydroxyethyl]pyrrolidin-3-ol was obtained from D-xylose by two different strategies through 3-C-cyano-3-deoxy-D-ribo-pentofuranose or 3-C-azidomethyl-3-deoxy-D-ribo-pentofuranose in 6 and 16% overall

  一锅反应中的氮杂糖是通过醛糖中氨基前体的催化还原反应，然后进行分子内还原性氨基烷基化反应而获得的。（3R，4S）-4-[（1S）-1,2-二羟乙基]吡咯烷-3-醇是通过两种不同的策略通过3-C-氰基-3-脱氧-D-核糖-戊呋喃糖从D-木糖获得的或3-C-叠氮基甲基3-脱氧-D-核糖-戊呋喃糖，总收率分别为6％和16％。在相应的Fmoc-氮杂糖中二醇基团的氧化裂解，然后脱保护，得到（3R，4R）-4-（羟甲基）吡咯烷丁-3-醇。（3R，4S）-4-[（1S，2R）-1,2,3-三羟丙基]吡咯烷-3-醇是由双丙酮-D-葡萄糖通过3-脱氧-3-C-硝基甲基-D-阿洛糖合成的总产率为7％。
• [EN] 3'-SUBSTITUTED METHYL OR ALKYNYL NUCLEOSIDES FOR THE TREATMENT OF HCV<br/>[FR] NUCLÉOSIDES MÉTHYLE OU ALCYNYLE SUBSTITUÉS EN POSITION 3 POUR LE TRAITEMENT DU VIRUS DE L'HÉPATITE C
  申请人：IDENIX PHARMACEUTICALS INC

  公开号：WO2015161137A1

  公开（公告）日：2015-10-22

  Provided herein are compounds, compositions and methods for the treatment of Flaviviridae infections, including HCV infections. In certain embodiments, compounds and compositions of nucleoside derivatives are disclosed, which can be administered either alone or in combination with other anti-viral agents. In certain embodiments, the compounds are 3'-substituted methyl or alkynyl nucleosides of Formula I: (I); or a pharmaceutically acceptable salt, solvate, stereoisomeric form, tautomeric form or polymorphic form thereof, wherein Base, PD, RA, RB1, RB2, RC and Z are as defined herein.

  本文提供了用于治疗黄病毒科感染的化合物、组合物和方法，包括HCV感染。在某些实施例中，披露了核苷衍生物的化合物和组合物，可以单独或与其他抗病毒药物联合使用。在某些实施例中，所述化合物是Formula I的3'-取代甲基或炔基核苷衍生物：(I)；或其药学上可接受的盐、溶剂化合物、立体异构体形式、互变异构体形式或多形形式，其中Base、PD、RA、RB1、RB2、RC和Z如本文所定义。
• Modeling the Adenosine Receptors:  Comparison of the Binding Domains of A_2A Agonists and Antagonists
  作者：Soo-Kyung Kim、Zhan-Guo Gao、Philippe Van Rompaey、Ariel S. Gross、Aishe Chen、Serge Van Calenbergh、Kenneth A. Jacobson

  DOI：10.1021/jm0300431

  日期：2003.11.1

  and validated with site-directed mutagenesis and the synthesis of chemically complementary agonists. Different binding modes of A(2A)AR antagonists and agonists were compared by using the FlexiDock automated docking procedure, with manual adjustment. Putative binding regions for the 9H-purine ring in agonist NECA 3 and the 1H-[1,2,4]triazolo[1,5-c]quinazoline ring in antagonist CGS15943 1 overlapped

  人类 A(2A) 腺苷受体 (AR) 及其对接配体的三维模型是通过与视紫质的同源性构建的，并通过定点诱变和化学互补激动剂的合成进行验证。通过使用 FlexiDock 自动对接程序和手动调整，比较了 A(2A)AR 拮抗剂和激动剂的不同结合模式。激动剂 NECA 3 中的 9H-嘌呤环和拮抗剂 CGS15943 1 中的 1H-[1,2,4] 三唑并[1,5-c] 喹唑啉环的推定结合区域重叠，并且每个的环外氨基都是 H-键合到 N(6.55) 的侧链。对于结合激动剂，核糖 3'-和 5'-取代基与亲水性氨基酸 T(3.36)、S(7.42) 和 H(7.43) 以及 5' 末端甲基之间形成 H 键 -尿醛酰胺与 F(6.44) 的疏水侧链相互作用。激动剂复合物的形成破坏了 A(2A)AR 的基态结构，该结构通过跨膜螺旋结构域 (TM) 区域中的氢键和疏水相互作用网络稳定，促进激活后的构象变化。TM6
• Exploring human adenosine A3 receptor complementarity and activity for adenosine analogues modified in the ribose and purine moiety
  作者：Philippe Van Rompaey、Kenneth A. Jacobson、Ariel S. Gross、Zhan-Guo Gao、Serge Van Calenbergh

  DOI：10.1016/j.bmc.2004.11.044

  日期：2005.2

  In this paper we investigated the influence on affinity, selectivity and intrinsic activity upon modification of the adenosine agonist scaffold at the 3- and 5'-positions of the ribofuranosyl moiety and the 2- and N-6-positions of the purine base. This resulted in the synthesis of various analogues, that is, 3-12 and 24-33, with good hA(3)AR selectivity and moderate-to-high affinities (as in 32, K-i = 27 nM). Interesting was the ability to tune the intrinsic activity depending on the substituent introduced at the 3'-position. (C) 2004 Elsevier Ltd. All rights reserved.
• Syntheses and biological evaluations of 3'-deoxy-3'-C-branched-chain-substituted nucleosides
  作者：Tai Shun Lin、Ju Liang Zhu、Ginger E. Dutschman、Yung Chi Cheng、William H. Prusoff

  DOI：10.1021/jm00055a006

  日期：1993.2

  Various 3'-deoxy-3'-C-(hydroxymethyl)-, 3'-deoxy-3'-C-(fluoromethyl)-, 3'-deoxy-3'-C-(azidomethyl)-, and 3'-deoxy-3'-C-(aminomethyl)-substituted nucleosides (total 12 compounds) have been synthesized and evaluated against L1210, P388, S-180, and CCRF-CEM cells and HSV-1, HSV-2, and HIV-1 in culture. Only 3'-deoxy-3'-C-(hydroxymethyl)thymidine (36) was found to show significant anticancer activity against L1210, P388, S-180, and CCRF-CEM cells with ED50 values of 50, 5, 10, and 1 muM, respectively. None of these compounds demonstrated significant antiviral activity against HSV-1, HSV-2, or HIV-1. These compounds were also evaluated against thymidine kinases derived from HSV-1 (strain KOS), HSV-2 (strain 333), and mammalian (K562) cells. The thymidine kinase (HSV-1 strain KOS) was inhibited significantly by both 3'-deoxy-3'-C-(hydroxymethyl)- and 3'-deoxy-3'-C-(fluoromethyl)thymidine.